A spike in weighing drug sales Mounaro Major pharmacies including shoes of high street firms have decreased, Lloyds Pharmacy And Superdrug,
Increase in demand Ellie comes after Lily, who creates Maunjaro, Announced that it has to be increased The cost of drug in Britain was 170 percent from September.
This means that a one month supply of the highest dose of the drug will increase from £ 122 to £ 330.
On social media, many users have stated that they are stocking drugs to avoid early price growth, despite the warning of Elie Lily and National Pharmacy Association (NPA).
The situation has made many pharmacies impact.
On Wednesday, Super Drug stated that it was out of stock for “foggy” on its website “due to national deficiency”. In a statement IndependentThe company said: “We are currently working hard to fulfill all the orders that are kept for silence, and we hope that the new customer can start accepting orders next week.
“Due to the nationwide high demand, we are experiencing delays with the stock of Maunzaro. To ensure the continuity of care, we are giving priority to the drug orders of existing superdrig patients who are currently using our weight loss services.”
Lloyds Pharmacy said on its website that it was out of the stock for new priscRibers of high doses of 10mg, 12.5mg and 15mg, while the boots online showed that it showed 7.5mg, 10mg, 12.5mg or 15mg pen.
Users usually begin at a weekly dose of 2.5mg as part of the weight loss plan, before the users move up to high doses.
Well -well pharmacy, which is the second largest pharmacy chain in the UK, said the supply of mounjaro from wholesalers has been “stalled” due to an increase in demand.
The company’s clinical product and innovation manager, Mital Thakrar, told Independent: “We are working hard with our wholesalers and manufacturers so that they can maintain stock supply in Well stores and we are currently in the stock of Maunzaro.”
The situation has also affected online pharmacies.
Pharmacy 2U said that it had seen a “significant short -term growth” after the announcement of the price hike, but that the spike had calmed down and it was giving priority to existing patients.
Simple Online Pharmacy said it had sold new patients to silence, while banning the sale of four weeks per patient to prevent bulk purchase. It said that it had “adequate” supply in all doses to complete repeat recipes.
Pharmacy said that it had also seen more people by ordering rival weight loss drug vegovi, which is a cheap option. Patients switching on the vegovi, who cost £ 85 per month, are advised to advise them to take a week’s break between two products.
Last week, Vegovi sales on a weight loss supplier Increased 2,600 percent after Mounjaro price hike.
Abdal Alvi, Chief Clinical Officer of Simple Online Healthcare, said that the pharmacy had seen all GLP -1 drug demands, including Vagovi and Maunzaro, the price hike has increased by 400 percent since the news.
The increase in demand has led to concerns in the pharmacy industry in the NPA, stating that it was said that the price hike was further known “preventing or stopping orders for high doses”.
Chairman Olivier Picard stated that buying bulk may have a “significant impact” on supply, while also presented a possible risk to patient safety through a possible decrease of regular check -up by the seller as part of weight loss management.
He urged patients to avoid unlicensed vendors, who could sell fake medicines that do not meet the UK safety standards.
Mr. Picard, who runs his own pharmacy, said: “The situation is serious at the moment. I have patients of online pharmacies and other brick and mortar pharmacies who are coming around, asking that ‘Have you got? I need a supply and my supplier has no stock’.
“I think wholesalers are completely overwhelmed by the demand of people trying to buy Munjaro.”
Elli Lily said she had allocation for the providers who order the stock from it, stating that it helped managing the supply and ensuring the patient’s access.
A spokesman told Independent: “Drugs and healthcare products are the legal protection implemented by the providers to prevent improper stockpiling of drugs.
“We encourage patients to order only on the basis of their current treatment scheme, so that the risk of localized disruption is reduced.”
The company’s decision to increase the price reflected efforts to align more closely to align the drug prices for Americans with political pressure from US President Donald Trump along with efforts to align prices more closely with its other European markets.
